Please login to the form below

basal insulin

This page shows the latest basal insulin news and features for those working in and with pharma, biotech and healthcare.

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

has compared it to Lantus (insulin glargine 100 units/mL), which lost its patent last year. ... The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its

Latest news

Sanofi exits Zynquista alliance with Lexicon

The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following
Success for AZ, setback for Sanofi in type 1 diabetes

There is a broad array of insulin products on the market, including short-acting versions used after meals and long-acting (basal) insulins designed to give background control of blood glucose, ... The decision is a blow to Sanofi’s hopes of rebuilding
FDA adcomm split on Sanofi’s type 1 diabetes drug

The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1 ... It is also a key element in Sanofi’s plans to rebuild its diabetes
FDA starts review of Sanofi’s oral type 1 diabetes drug

Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine
CHMP recommends Teva's generic version of Astellas' Advagraf

This would allow its use in combination with basal insulin, where the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.

More from news
Approximately 0 fully matching, plus 87 partially matching documents found.

Latest Intelligence

Harnessing commercial innovation

products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. ... We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan.
Going the distance

The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from
Interview: Pierre Chancel, Sanofi Diabetes

ORBIT (Observational Registry for Basal Insulin Treatment) is a study focused on type 2 diabetes in China and the result of Sanofi's partnership with the CDS and George Institute for ... The company sees particular potential for Lyxumia as a combination